Abstract YO3
Case summary
METASTATIC BREAST CANCER TO ESOPHAGUS: A CASE REPORT AND REVIEW OF THE LITERATURE
Secondary esophageal carcinoma from a breast primary is an infrequent phenomenon occurring in around 0.4% of patients. It is pertinent to rule out esophageal metastasis when a patient of breast carcinoma present with dysphagia after a long DFS. Most esophageal metastasis are usually submucosal deposition, requiring EUS-FNB for diagnosis. Given the rarity of this presentation and failure of diagnosis by simple mucosal biopsy during patient’s lifetime, there is a general lack of consensus on management guidelines in these patients.
Herein we report a case of 65 year old female presented with dysphagia who was subsequently diagnosed with esophageal metastases, 14years post surgery for breast cancer. She was treated with a combination of systemic Chemotherapy, hormonal therapy and local radiotherapy comprising both external beam radiotherapy(EBRT) and Intraluminal radiotherapy(ILRT). We also performed a comprehensive review of literature on esophageal metastases from breast primary, aiming to improve the diagnostic accuracy and treatment efficacy in this rare presentation. Our patient tolerated the treatment well and achieved a significant symptomatic improvement post Radiotherapy. Reviewing various literature, we observed 83% patients presented with complaints of dysphagia after a median of 13 years post breast surgery, with 72% metastases involving mid thoracic esophagus while majority were hormonally receptive.
We conclude that patients presenting with dysphagia post breast cancer treatment, should undergo EUS-FNB to rule out esophageal metastasis. While surgical interventions were effective treatment in some cases, we suggest systemic Chemotherapy with Hormonal therapy, and radiotherapy for local control as the management of choice in these patients. Even though prognosis is difficult to predict , this combined modality of treatment seems to achieve a better overall survival.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
461P - Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India
Presenter: Nitin Murthy
Session: Poster viewing 06
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06